Takeda Makes $1 Billion Move For Amgen Development Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement includes Japanese rights to Vectibix.
You may also be interested in...
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Negative news increases pressure on Japanese pharma's oncology subsidiary Millennium Pharmaceuticals to perform.
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Negative news increases pressure on Japanese pharma's oncology subsidiary Millennium Pharmaceuticals to perform.